Lumos Diagnostics Holdings Ltd (ASX: LDX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Lumos Diagnostics Holdings Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $17.33 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 481.31 million
Earnings per share -0.021
Dividend per share N/A
Year To Date Return -50.68%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Lumos Diagnostics Holdings Ltd (ASX: LDX)
    Latest News

    Young doctor raising arms in air with hands in fists celebrating a new development
    Healthcare Shares

    3 ASX healthcare shares rocketing 20% to 100% today

    These ASX shares are thumping the market on Tuesday and making their shareholders smile.

    Read more »

    Man pointing at a blue rising share price graph.
    Healthcare Shares

    Lumos Diagnostics share price rockets 1,036% in 2 days on FDA news

    Investors are sending the Lumos Diagnostics share price through the roof following news from the US Food and Drug Administration.

    Read more »

    A woman holds a glowing, sparking, technological representation of a planet in her hand.
    Ask a Fund Manager

    Expert reveals one IPO he's absolutely pumped about. When will it hit the ASX?

    Ask A Fund Manager: SG Hiscock's Rory Hunter tells why he's looking forward to one possible listing coming up later…

    Read more »

    Two kids in superhero capes.
    Ask a Fund Manager

    2 small-cap ASX shares to handsomely reward patient investors

    Ask A Fund Manager: SG Hiscock's Rory Hunter reveals the 2 little-known stocks that will put smiles on investor faces…

    Read more »

    A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
    Coronavirus News

    Why are ASX COVID test shares climbing today?

    COVID-19 tests are in focus again today.

    Read more »

    a group of young people dance together with their hands in the air, moving to music.
    Healthcare Shares

    The Lumos Diagnostics (ASX:LDX) share price is soaring another 8% today. Here's why

    The company's shares are continuing their positive run in February.

    Read more »

    Rapid Antigen Test taking place.
    Healthcare Shares

    Why the Lumos Diagnostics (ASX:LDX) share price is up 15% today

    The company's shares are on the move today...

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Share Gainers

    AnteoTech (ASX:ADO) share price gains 42% in a week amid RAT race

    The demand for rapid antigen tests appear to be pushing the company's shares higher.

    Read more »

    a group of doctors and medical staff in uniform high five in celebration in a hospital setting
    Healthcare Shares

    Lumos Diagnostics (ASX:LDX) share price climbs amid RAT mania

    Lumos share price rises amid RAT test drama

    Read more »

    Share Gainers

    Lumos Diagnostics (ASX:LDX) share price up 9% on evaluation update

    Another gust of wind behind Lumos Diagnostics' shares today.

    Read more »

    doctor and nurse attend to patient bedside in medical setting
    IPOs

    Lumos Diagnostics (ASX:LDX) share price adds 9% on IPO, raising $63m

    Lumos hits the ASX, riding COVID testing momentum.

    Read more »

    LDX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Lumos Diagnostics Holdings Ltd

    Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

    LDX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 May 2024 $0.04 $0.00 0.00% 3,892,236 $0.04 $0.04 $0.03
    23 May 2024 $0.04 $0.00 0.00% 4,633,726 $0.04 $0.04 $0.04
    22 May 2024 $0.04 $0.00 0.00% 4,493,295 $0.04 $0.04 $0.04
    21 May 2024 $0.04 $0.00 0.00% 330,186 $0.04 $0.04 $0.04
    20 May 2024 $0.05 $0.00 0.00% 1,280,977 $0.05 $0.05 $0.04
    17 May 2024 $0.05 $0.00 0.00% 1,286,122 $0.05 $0.05 $0.05
    16 May 2024 $0.05 $0.00 0.00% 1,174,462 $0.05 $0.05 $0.05
    15 May 2024 $0.05 $0.00 0.00% 233,200 $0.05 $0.05 $0.05
    14 May 2024 $0.05 $0.00 0.00% 536,685 $0.05 $0.05 $0.05
    13 May 2024 $0.05 $0.00 0.00% 370,312 $0.05 $0.05 $0.05
    10 May 2024 $0.05 $0.00 0.00% 416,027 $0.05 $0.05 $0.05
    09 May 2024 $0.05 $0.00 0.00% 29,402,136 $0.05 $0.05 $0.05
    08 May 2024 $0.05 $0.00 0.00% 1,136,936 $0.05 $0.05 $0.05
    07 May 2024 $0.05 $0.00 0.00% 1,505,990 $0.05 $0.05 $0.05
    06 May 2024 $0.05 $0.00 0.00% 4,447,151 $0.05 $0.06 $0.05
    03 May 2024 $0.05 $0.00 0.00% 3,001,215 $0.05 $0.05 $0.05
    02 May 2024 $0.05 $0.00 0.00% 1,624,885 $0.05 $0.05 $0.05
    01 May 2024 $0.05 $0.00 0.00% 3,802,333 $0.05 $0.05 $0.05
    30 Apr 2024 $0.05 $0.00 0.00% 3,305,091 $0.05 $0.05 $0.05
    29 Apr 2024 $0.05 $0.00 0.00% 2,421,594 $0.06 $0.06 $0.05

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 Oct 2023 Doug Ward Buy 250,000 $21,645
    On-market trade.
    03 Aug 2023 Bronwyn Le Grice Issued 71,428 $5,000
    Participation in share purchase plan.
    03 Aug 2023 Catherine Robson Issued 428,571 $30,000
    Participation in share purchase plan.
    03 Aug 2023 Samuel Lanyon Issued 285,714 $20,000
    Participation in share purchase plan.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Bronwyn Joyce Le Grice Non-Executive Director Nov 2020
    Ms Le Grice has more than 18 years of executive experience in the health technology sector spanning commercialization, venture capital, corporate development, capital raising and industry advocacy. Formerly an Investment Director with leading healthcare investment firm, BioScience Managers, Ms. Le Grice managed over $65M of private and public equity capital raisings and was actively involved in over $30M of portfolio investments. In 2017, she founded ANDHealth, Australia's only dedicated digital health accelerator and commercialization support organization which has led to significant growth within Australia's nascent digital health sector. Ms. Le Grice holds a number of health, technology and innovation advisory roles both in Australia and internationally, and is a Director of ANDHealth Pty Ltd. He is Chair of the Disclosure Committee and risk comittee
    Ms Catherine Robson Non-Executive Director Dec 2020
    Ms Robson has more than 20 years of experience in management, finance and investment. Ms. Robson currently chairs the Board of fully owned subsidiary Equity Trustees Superannuation Limited. Ms. Robson's other Board appointments include serving as a Non-Executive Director for Australia's largest customer owned bank, Newcastle Greater Mutual Group, where she chairs the Audit Committee. She is chairman of Risk Committee.
    Ms Lawrence Mehren Non-Executive Deputy ChairmanNon-Executive Director Dec 2020
    Mr Mehren served as President and Chief Executive Officer as well as a Director of Accelerate Diagnostics from 2012 to 2020. During his tenure, the company developed and launched its groundbreaking Accelerate Pheno instrument. Prior to this, Mr. Mehren was the Head of Global Business for Ventana Medical Systems and Roche Tissue Diagnostics managing its four business units. He also held various global leadership positions with Ventana including Senior Vice President of Emerging Businesses and Chief Financial Officer. Mr. Mehren was also Managing Director, Partner and Head of P&M Corporate Finance's life sciences practice
    Mr Samuel Ross Garland Lanyon Non-Executive ChairmanNon-Executive Director Jun 2022
    Mr Lanyon has more than 25 years of experience in strategy, sales and operations with a track record in the global commercialization of technology rich healthcare products. Mr. Lanyon currently serves as Executive Director and co-founder of Planet Innovation and a Non-Executive Director of Paragon Funds Management. He also serves as a Non-Executive Director of Visus Therapeutics, a clinical-stage company focused on developing innovation medicines to improve vision. Previously, Mr. Lanyon held international executive roles with Leica Microsystems, part of Danaher Corporation. He is a member of Member of the Disclosure Committee and risk committee.
    Mr Doug Ward Chief Executive OfficerManaging Director Jun 2022
    Mr Ward has 30 years experience as an executive in the diagnotics and healthcare industries. He joined from his previous role at the leading US womens healthcare company, Hologic. Prior to this, Doug was CEO of PDGX, a genomics in vitro diagnostics company that was acquired by LabCorp in 2022.
    Ms Melanie Jaye Leydin Chief Financial OfficerCompany Secretary
    -
    Ms Tracy Weimar Company Secretary
    -
    Barrie Lambert Chief Financial Officer
    -
    Melanie Jaye Leydin Chief Financial OfficerCompany Secretary
    -
    Tracy Weimar Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Planet Innovation Holdings Limited 68,021,060 21.98%
    National Nominees Limited 59,260,190 19.15%
    GZ Family Holdings Pty Ltd (Gz Family A/C) 21,930,614 7.09%
    J P Morgan Nominees Australia Pty Limited 18,765,171 6.06%
    Hsbc Custody Nominees (Australia) Limited 14,161,707 4.58%
    Palm Beach Nominees Pty Limited 9,169,876 2.96%
    H&G Investment Management Ltd (H&G Vail Lane Fund A/C) 9,000,000 2.91%
    Hgl Investments Pty Ltd 6,000,000 1.94%
    Comsec Nominees Pty Limited 5,827,821 1.88%
    Mr James Stirling Whyte 5,000,000 1.62%
    Bowvale Investments Pty Limited (Bowvale Investments S/F A/C) 4,312,095 1.39%
    Paranji Super Fund Pty Ltd (Paranji Superfund A/C) 4,000,000 1.29%
    Lind Global Fund Ii Lp 3,982,979 1.29%
    Mr Kah Choon Wai 3,500,000 1.13%
    Morsec Nominees Pty Ltd (Accumulation Account) 2,897,241 0.94%
    Pineleaf Pty Limited (Smithers Super Fund A/C) 2,782,792 0.90%
    Warbont Nominees Pty Ltd (Unpaid Entrepot A/C) 2,757,355 0.89%
    Netshare Nominees Pty Ltd 2,656,571 0.86%
    Third Party Nominees Pty Ltd (Accumulation A/C) 2,494,084 0.81%
    Oceanview Victoria Pty Ltd (Oceanview Family A/C) 2,000,000 0.65%

    Profile

    since

    Note